Tradestie Institutional Equity Comparison Engine
PEN vs DXCM โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
DXCM Overall Edge
DXCM Captures Institutional Edge (4โ0 Pillars ยท 7โ3 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to DexCom, Inc. (DXCM) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, PEN trades at 53.1x Forward P/E with 12.1% operating margin (+15.6% YoY revenue) versus DXCM at 25.3x Forward P/E and 24.0% operating margin (+11.2% YoY). In options structure, PEN sits in UNCLASSIFIED (96th %ile IV; Dealer Gamma Walls on Pro) against DXCM sits in CONSOLIDATION (15th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
DXCM
PEN 53.1x vs DXCM 25.3x Fwd P/E
Growth & Margin Winner
DXCM
Op Margin 12.1% vs 24.0% ยท YoY +15.6% vs +11.2%
Momentum & Technical Winner
DXCM
1Y +12.7% vs +32.8% ยท 52W Pos 50% vs 63%
Options & Structure Winner
DXCM
UNCLASSIFIED (96th %ile IV) vs CONSOLIDATION (15th %ile IV)
PEN
NYSE
Penumbra, Inc.
Surgical & Medical Instruments & Apparatus
$319.12
-0.28% 1D
Market Cap
$12.6B
1M Return
-1.8%
1Y Return
+12.7%
Forward P/E
53.1x
Unified AI Score
52.2 / 100
HOLD
Tech 55.0
Fund 56.0
Flow 63.0
Mom 46.0
DXCM
NASDAQ
DexCom, Inc.
Surgical & Medical Instruments & Apparatus
$79.32
-1.08% 1D
Market Cap
$29.9B
1M Return
+1.28%
1Y Return
+32.8%
Forward P/E
25.3x
Unified AI Score
50.8 / 100
HOLD
Tech 49.0
Fund 56.0
Flow 68.0
Mom 54.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PEN +12.7%
DXCM +32.8%
Spread: +20.1 pp (DXCM Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PEN Revenue | DXCM Revenue | PEN Op. Margin | DXCM Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2018 | $440M | $1.03B | -0.2% | -18.1% | PEN |
| FY2019 | $550M | $1.48B | 8.7% | 9.6% | DXCM |
| FY2020 | $560M | $1.93B | -6.9% | 15.5% | DXCM |
| FY2021 | $750M | $2.45B | -1.0% | 10.9% | DXCM |
| FY2022 | $850M | $2.91B | 0.7% | 13.4% | DXCM |
| FY2023 | $1.06B | $3.62B | 6.9% | 16.5% | DXCM |
| FY2024 | $1.19B | $4.03B | 0.8% | 14.9% | DXCM |
| FY2025 | $1.40B | $4.66B | 13.5% | 19.6% | DXCM |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PEN | DXCM | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $12.6B | $29.9B | Larger Scale | DXCM |
| Trailing P/E Ratio Valuation | 80.6x | 31.6x | Lower Multiple | DXCM |
| Forward P/E Ratio Valuation | 53.1x | 25.3x | Lower Multiple | DXCM |
| Revenue Growth (YoY) Growth | +15.6% | +11.2% | Higher Growth | PEN |
| Operating Margin (TTM) Profitability | 12.1% | 24.0% | Higher Margin | DXCM |
| Net Profit Margin Profitability | 10.1% | 19.4% | Higher Margin | DXCM |
| Return on Equity (ROE) Capital Efficiency | 10.7% | 37.7% | Higher ROE | DXCM |
| 52-Week Range Position Momentum | 50% ($277โ$362) | 63% ($57โ$93) | Stronger Trend | DXCM |
| Beta / 30D Volatility Risk Regime | 0.10ฮฒ ยท 10% Vol | 0.59ฮฒ ยท 43% Vol | Lower Realized Risk | PEN |
| Unified Institutional Score Composite Signal | 52.2 / 100 (HOLD) | 50.8 / 100 (HOLD) | Higher Composite | PEN |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PEN vs DXCM Buy Guide
PEN
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
96th %ile
IV Regime
Extreme (>80th %ile)
DXCM
CONSOLIDATION
73d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
15th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PEN nor DXCM registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.